Last reviewed · How we verify
tretinoin 0.025% cream
Tretinoin is a vitamin A derivative that binds to retinoic acid receptors to regulate gene expression, promoting cell differentiation and reducing sebum production and comedone formation.
Tretinoin is a vitamin A derivative that binds to retinoic acid receptors to regulate gene expression, promoting cell differentiation and reducing sebum production and comedone formation. Used for Acne vulgaris, Photoaging and fine wrinkles, Hyperpigmentation.
At a glance
| Generic name | tretinoin 0.025% cream |
|---|---|
| Also known as | Tretinoin |
| Sponsor | Wake Forest University |
| Drug class | Retinoid |
| Target | Retinoic acid receptors (RAR-alpha, RAR-beta, RAR-gamma) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Tretinoin acts as a ligand for nuclear retinoic acid receptors (RAR and RXR), which modulate transcription of genes involved in cell proliferation and differentiation. In the skin, it increases cell turnover, normalizes keratinization, and reduces follicular plugging. It also has anti-inflammatory properties and stimulates collagen remodeling, making it effective for both acne and photoaging.
Approved indications
- Acne vulgaris
- Photoaging and fine wrinkles
- Hyperpigmentation
Common side effects
- Erythema and irritation
- Peeling and dryness
- Photosensitivity
- Burning or stinging
Key clinical trials
- Comparison of Efficacy of Metformin Gel 30% vs Triple Combination Cream (Hydroquinone 4%, Flucinolone Acetonide 0.01%, Tretinoin 0.025%) in Treatment of Melasma in Tertiary Care Hospital Karachi (NA)
- Effectiveness and Safety of Zingiber Officinale Transdermal Patch for Acne Vulgaris; Study of Interleukin 1 and Skin Microbiome (PHASE2, PHASE3)
- Efficacy Of Combined Microneedling Plus Tretinoin In Treatment Of Stria Rubra (PHASE1)
- Efficacy, Safety Profile, and Post-Acne Sequelae of 0.025% Retinoic Acid Cream vs. 0.1% Adapalene Cream in Mild Acne Vulgaris in Fitzpatrick Skin Types III-V (PHASE1, PHASE2)
- The Efficacy Tretinoin Cream in the Treatment of Axillary Hyperpigmentation Associated With Acanthosis Nigricans (PHASE3)
- A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris (EARLY_PHASE1)
- Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris (PHASE4)
- Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tretinoin 0.025% cream CI brief — competitive landscape report
- tretinoin 0.025% cream updates RSS · CI watch RSS
- Wake Forest University portfolio CI